StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines Non-GAAP Adjusted Research & Development Expense by Quarter

Non-GAAP Adjusted Research & Development Expense ($M) ($M)

QuarterlyAnnual

BeOne Medicines Non-GAAP Adjusted Research & Development Expense: $534M in Q2 2026, up 20.2% from a year earlier.

Latest, Q2 2026
534
Period ended Jun 30, 2026
Change on a year earlier
+20.2%
444 in Q2 2025
History
15 quarters
Since Q4 2022
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Adjusted research and development | $ | 533,950 | $ | 444,057 | $ | 999,854 | $ | 865,252”

Source: Form 8-K (filed 2026-08-05) ↗

Reported in Form 8-K EX-99.1 Non-GAAP Reconciliation Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Adjusted Research & Development Expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026534+20.2%Form 8-K (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026466+10.6%Form 8-K (filed 2026-05-06) ↗
Q4 2025Dec 31, 2025545+14.7%Form 8-K (filed 2026-02-26) ↗
Q3 2025Sep 30, 2025446+10.0%Form 8-K (filed 2025-11-06) ↗
Q2 2025Jun 30, 2025444+16.1%Form 8-K (filed 2025-08-06) ↗
Q1 2025Mar 31, 2025421+3.9%Form 8-K (filed 2025-05-07) ↗
Q4 2024Dec 31, 2024475+8.6%Form 8-K (filed 2025-02-27) ↗
Q3 2024Sep 30, 2024406+2.4%Form 8-K (filed 2024-11-12) ↗
Q2 2024Jun 30, 2024383+5.2%Form 8-K (filed 2024-08-07) ↗
Q1 2024Mar 31, 2024405+12.1%Form 8-K (filed 2024-05-08) ↗
Q4 2023Dec 31, 2023437+8.2%Form 8-K (filed 2024-02-26) ↗
Q3 2023Sep 30, 2023396–Form 8-K (filed 2024-11-12) ↗
Q2 2023Jun 30, 2023364–Form 8-K (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023362–Form 8-K (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022404–Form 8-K (filed 2024-02-26) ↗

Cite this data

StockData. (2026). BeOne Medicines Non-GAAP Adjusted Research & Development Expense ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj-rd-exp

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.